About Acclarent
Acclarent is a company based in Irvine (United States) founded in 2004 was acquired by Integra LifeSciences in December 2023. Acclarent has raised $61 million across 3 funding rounds from investors including Integra LifeSciences, Johnson & Johnson Innovation – JJDC and NEA. The company has 349 employees. Acclarent operates in a competitive market with competitors including Intersect ENT, Tivic Health, Entellus Medical, MyPurMist and Dalent Medical, among others.
- Headquarter Irvine, United States
- Employees 349
- SectorsHealthcare
- Website acclarent.com
- Social LinkedIn
- Acquired by Ethicon (Dec 2009)
- Legal Name Acclarent, Inc
- Total Equity Funding$61M (USD)
in 3 rounds
- Latest Funding Round$26M (USD), Series D
Jan 2009
- InvestorsIntegra LifeSciences
& 6 more
- Employee Count349
- Acquired by
Funding Insights of Acclarent
Acclarent has successfully raised a total of $61M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $26 million completed in January 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $61M
- Total Rounds 3
- Last Round Series D — $26M
- Investors Count 5
All 3 funding rounds of Acclarent with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2009 | $26M | Series D | – | – | |
| Apr 2007 | $35M | Series C | – | Meritech | |
| Dec 2005 | – | Series B | – | – | – |
7 investors in total: 7 institutional.
Investors in Acclarent
Acclarent has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Integra LifeSciences, Johnson & Johnson Innovation – JJDC and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm backed by Johnson & Johnson | – | jnjinnovation.com/jjdc | Cambridge, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Investments are made in life sciences firms across all stages. | – | delphiventures.com | Menlo Park, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
Private equity investments are directed toward US-based companies. | – | meritechcapital.com | Palo Alto, United States | |
Specializes in surgical sutures and wound closure devices. | 1886 | ethicon.com | Cincinnati, United States | |
Diversified medical devices are developed for healthcare applications. | 1989 | integralife.com | Plainsboro, United States |
Investor details for Acclarent
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Acclarent
1 people are tracked at Acclarent (1 in leadership); the tracked headcount is 349.
| Name | Role | Group |
|---|---|---|
Jeff Hopkins | CEO | Leadership |
Complete people profiles for Acclarent
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Acclarent
5 dated milestones of Acclarent across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Acclarent is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $26.0M.
- Exit Acquired by Ethicon.
- Exit Acquired by Integra LifeSciences.
Competitors of Acclarent
Acclarent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Intersect ENT, Tivic Health, Entellus Medical, MyPurMist and Dalent Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| intersectent.com | 2003 | Menlo Park, United States | $76.53M | 371 | Drug-releasing implants for sinusitis treatment are developed. | |
| tivichealth.com | 2016 | Menlo Park, United States | $8M | 16 | Bioelectronic devices for sinusitis pain relief are developed. | |
| entellusmedical.com | 2006 | Plymouth, United States | $90.53M | 286 | Minimally invasive products for chronic sinusitis treatment are developed. | |
| mypurmist.com | 2001 | Concord, United States | $8.89M | 5 | Medical humidification devices are developed with patented CFV technology. | |
| dalentmedical.com | 2017 | Coral Gables, United States | $3.45M | – | Balloon-based sinus dilation devices are developed for sinusitis treatment. | |
| sinusafe.com | 2015 | Kiryat Ono, Israel | – | – | Sinus lavage device for sinusitis patients is developed without surgery. | |
| jedersystem.com | 2010 | Vienna, Austria | $732,000 | – | Minimally invasive sinus lift system | |
| ststent.com | 2013 | Misgav, Israel | $450,000 | – | Flexible nasal stent | |
| bioinspiretechnologies.com | 2009 | Palo Alto, United States | $3.12M | 7 | Specializes in interventional medical devices development. |
Detailed competitors of Acclarent
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Acclarent
Websites that share an audience with Acclarent (acclarent.com).
Websites whose visitors overlap most with Acclarent. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
balloonsinuplasty.com | balloonsinuplasty.com | 100% | – | – | – |
mma.org.my | mma.org.my | 83% | – | #909,053 | – |
| dynatronics.com | 81% | 5K | #3,270,778 | View details | |
collincountyent.com | collincountyent.com | 80% | – | #2,704,791 | – |
hydromedonline.com | hydromedonline.com | 76% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Acclarent
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Acclarent
Complete news archive for Acclarent
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Acclarent
10 companies that operate in the same segment as Acclarent (ENT Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Electronic hearing devices and implants are developed for hearing loss. | 1981 | Mumbai, Maharashtra, India | – | USD 1.6 B | 5,500 | |
Medicines are developed to protect, repair, and restore hearing capacity. | 2015 | Cambridge, Massachusetts, United States | USD 169.53 M | – | 62 | |
Small molecule therapeutics for ENT diseases are developed. | 2005 | Watertown, United States | USD 127.61 M | USD 1.53 M | 30 | |
Hearing loss treatment devices are developed by WS Audiology. | 2019 | Allerød, Denmark | – | – | – | |
Neuromodulation treatments for tinnitus are provided using bi-modal technology. | 2010 | Dublin, Ireland | USD 54.59 M | – | – | |
Provider of 3D ear scanning systems | 2000 | Copenhagen, Denmark | USD 36.01 K | – | 1 | |
Hearing aids are supplied for individuals with hearing disabilities. | 2010 | San Jose, California, United States | USD 216.58 M | – | 45 | |
Provider of advanced cochlear implants and hearing technology for powerful connections | 1993 | Valencia, California, United States | USD 78.06 M | USD 4.93 M | 20 | |
Hearing aids are developed for unique conditions with enhanced amplification. | 1956 | Copenhagen, Denmark | USD 5.38 M | – | – | |
Developer of gene therapies to restore and preserve hearing capabilities in genetically defined populations | 2016 | Boston, Massachusetts, United States | USD 162.65 M | – | 92 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Acclarent
Acclarent was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Acclarent is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Jeff Hopkins is the current CEO of Acclarent.
Acclarent is a funded company, having raised a total of $61M across 3 funding rounds to date.
Acclarent has 349 employees.
Acclarent was founded in 2004 in Irvine, United States, within the medical device sector. Minimally invasive technologies for ear, nose, and throat procedures are developed by the company, focusing on balloon-based sinuplasty to address rhinosinusitis and persistent Eustachian tube dysfunction. Nasal anatomy is preserved through these tools, which support surgeons in clinical applications across the region.
Acclarent's top competitors include Tivic Health, Intersect ENT and Entellus Medical.
Acclarent has 7 investors. Key investors include Integra LifeSciences, Johnson & Johnson Innovation – JJDC, NEA, Delphi Ventures, and Versant Ventures.
Acclarent operates through Acclarent, Inc.
Yes. Acclarent was acquired by Ethicon in December 2009.